Pharmacotherapy for diabetic peripheral neuropathy pain and quality of life

Waldfogel, Julie M.; Nesbit, Suzanne; Dy, Sydney M.; Sharma, Ritu; Zhang, Allen; Wilson, Lisa M; Bennett, Wendy L.; Yeh, Hsin-Chieh; Chelladurai, Yohalakshmi; Feldman, Dorianne; Robinson, Karen A.

doi:10.1212/wnl.0000000000003882

Cited by 139 publications

(106 citation statements)

References 38 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Studies were however short term and drugs had substantial discontinuation rates of~10%. 96 The limited benefit of any one agent alone reflects the complex etiologic basis of neuropathic pain. Thus, there is an increasing recognition that "one size does not fit all," and rather than having an agnostic approach (ie, blindly trying different therapies until one works), we should consider better clinical phenotyping and targeted therapies.…”

Section: Symptomatic Treatment Of Dpnmentioning

confidence: 99%

Diabetic Peripheral Neuropathy: Epidemiology, Diagnosis, and Pharmacotherapy

Iqbal

Azmi

Yadav

et al. 2018

Clinical Therapeutics

355

249

View full text Add to dashboard Cite

show abstract

Section: Symptomatic Treatment Of Dpnmentioning

confidence: 99%

Diabetic Peripheral Neuropathy: Epidemiology, Diagnosis, and Pharmacotherapy

Iqbal

Azmi

Yadav

et al. 2018

Clinical Therapeutics

355

249

View full text Add to dashboard Cite

show abstract

“…Smith and his colleagues reported that treatment for pain intensity only did not result in any improvement of the QoL of patients with trigeminal nerve injuries (Smith et al, ). A recently published systematic review on the effect of pharmacotherapy for diabetic peripheral neuropathy pain and quality of life stated that contrary to the significant analgesic effect of duloxetine, venlafaxine and other analgesics, QoL was poorly reported because few studies reported this value (only when the results were significant) or the results were inconsistent (Waldfogel et al, ). As a result, it may be inappropriate to consider the effect of analgesics and alleviation of pain intensity only when we are trying to treat the complexed NeP and improve QoL of patients.…”

Section: Introductionmentioning

confidence: 99%

Depression as a mediator of quality of life in patients with neuropathic pain: A cross‐sectional study

Liu

2019

Journal of Advanced Nursing

View full text Add to dashboard Cite

Aims To explore whether pain intensity has an indirect effect on quality of life through mediation of depression in patients with neuropathic pain (NeP). Design An observational, questionnaire‐based, cross‐sectional study. Methods A convenience sample of patients suffering from NeP were enrolled from June 2015 ‐ May 2016. Three questionnaires were used to collect data of pain intensity, Quality of life and depression. Andrew Hayes' PROCESS macro modelling tool for the SPSS software, based on the mediation Bootstrap confidence interval method, was used to analyse the mediation effect. Results Both pain intensity and depression correlated negatively with the quality of life of patients. The indirect effect of pain intensity on the quality of life through depression was negative. Conclusions Increased pain intensity and depression were associated with a decreased quality of life in patients suffering from NeP and pain intensity had an indirect effect on the quality of life of patients through depression. Impact A low quality of life and depression are commonly seen in patients with NeP. However, little is known about the relationship between pain, quality of life and depression. Both pain intensity and depression had some negative effect on quality of life in patients with NeP. Pain intensity had an indirect effect on quality of life through a mediation effect of depression in patients with NeP. When caring for patients with NeP, nurses should assess depression routinely and try to alleviate it.

show abstract

“…Hempe et al [59] evaluated if nephropathy and neuropathy in ZDF rats are linked to the hyperglycemic state of the rats and are real diabetic late complications or are related to other characteristics of the fa/fa genotype. Good glycemic control may be effective in delaying the neuropathic symptoms in diabetic patients [66].…”

Section: Zucker Diabetic Fatty Ratsmentioning

confidence: 99%

Zucker Diabetic Fatty Rats for Research in Diabetes

Capcarová¹,

Kalafová²

2020

Animal Models in Medicine and Biology

View full text Add to dashboard Cite

The rising incidence of diabetes mellitus (DM) worldwide presents a global public health problem. DM is classified into two main groups: type 1 (T1DM) and type 2 (T2DM). T1DM requires insulin treatment. T2DM is complex, heterogeneous, polygenic disease defined primarily by insulin resistance, ongoing hyperglycemia, and β cells' dysfunction. For research in diabetes, an appropriate experimental model reflecting symptoms and complications of human T2DM is required for understanding the pathogenesis, molecular nature, and the possibilities of the treatment. Among the many animal models, rodent models that develop DM spontaneously are frequently used in the studies due to their similarity to the humans and economic effectiveness. This work gives a detailed overview of the literature, covering the characteristic of DM, its symptoms and complications, the description of Zucker diabetic fatty (ZDF) rats as an appropriate model for research in T2DM, and the possibility of the treatment.spontaneously diabetic Tori (SDT) rats, Kuo Kondo (KK) mice, ob/ob+/+ mice, and db/db+/+ mice [84]. GK rats are nonobese Wistar substrain which develops T2DM early [86]. Male OLETS rats suffer from diabetes at 18-25 weeks of age. The symptoms include polyphagia, mild obesity, hypertriglyceridemia, hyperinsulinemia, and impaired glucose tolerance in 16 weeks of age [87]. Tori SDT rat is inbred strain of Sprague-Dawley rat. Male individuals have high glucose levels by 20 weeks, pancreatic islet histopathology, hemorrhage in pancreatic islets, and inflammatory cell infiltration with fibroblasts, prior to diabetes glucose intolerance with hypoinsulinemia [88].KK mice are a polygenic model of obesity and T2DM. They are characterized by insulin resistance, hyperinsulinemia, and hyperphagia [89]. The ob/ob+/+ mice carry a mutation in the leptin gene, manifested as obesity, hyperglycemia, impaired glucose intolerance, and hyperinsulinemia [90]. The db/db+/+ mice have a leptin receptor mutation, are spontaneously hyperphagic, and suffer from obesity, hyperglycemia, hyperinsulinemia, and insulin resistance within the first month of life [91]. The advantages of ZDF rats in diabetes research are mainly due to the fact that it is a spontaneous model for T2DM research. It shows characteristics such as hyperglycemia, obesity, hyperphagia, polyuria, insulin disorders, and dyslipidemia due to the mutation in the leptin receptor gene and provides an appropriate model for common human T2DM. Moreover, these rats are calm and dispassionate; the handling and manipulation with them is comfortable.

show abstract

Pharmacotherapy for diabetic peripheral neuropathy pain and quality of life

Cited by 139 publications

References 38 publications

Diabetic Peripheral Neuropathy: Epidemiology, Diagnosis, and Pharmacotherapy

Diabetic Peripheral Neuropathy: Epidemiology, Diagnosis, and Pharmacotherapy

Depression as a mediator of quality of life in patients with neuropathic pain: A cross‐sectional study

Zucker Diabetic Fatty Rats for Research in Diabetes

Contact Info

Product

Resources

About